Elizabeth J. Linder
Direktor/Vorstandsmitglied bei Asia Scotland Initiative
Profil
Elizabeth J.
Linder is currently a Director at MMV Medicines for Malaria Venture and a Trustee at Asia Scotland Initiative.
Aktive Positionen von Elizabeth J. Linder
| Unternehmen | Position | Beginn |
|---|---|---|
Asia Scotland Initiative
 Asia Scotland Initiative Miscellaneous Commercial ServicesCommercial Services Asia Scotland Initiative promotes understanding and collaboration between Scotland and Asia. The company was founded by Roddy Gow and is headquartered in Edinburgh, the United Kingdom. | Direktor/Vorstandsmitglied | - |
MMV Medicines for Malaria Venture
 MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Asia Scotland Initiative
Asia Scotland Initiative Miscellaneous Commercial ServicesCommercial Services Asia Scotland Initiative promotes understanding and collaboration between Scotland and Asia. The company was founded by Roddy Gow and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
MMV Medicines for Malaria Venture
MMV Medicines for Malaria Venture Miscellaneous Commercial ServicesCommercial Services MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland. | Commercial Services |
